3.0
Dec 31, 2017
Anonymous employee
Former employee, less than 1 year
London, England
Recommend
CEO approval
Business Outlook
Pros
Truly innovative company from an R and D perspective, excellent variation in their pipeline that has real potential.
Cons
it is obvious that this company is used to partnering with other companies who have the knowledge to commercialise their drugs as there is hardly any capability internally to commercialise their drugs internally in a competitive manner. additionally there appears to be a mis match between commercial outcomes and the level of investment needed to achieve these outcomes